BPC-157 is an experimental peptide, not an FDA-approved human medication. Online products are often sold as “research use only,” and safety, dosing, purity, and effectiveness in people are not established. Chia does not offer BPC-157; patients should discuss symptoms or recovery goals with a licensed clinician instead of self-injecting online peptides.
Wondering if NAD+ is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you buy BPC-157 peptide online?
You may find BPC-157 sold online, but that does not mean it is a patient-ready medication. Many listings frame it as a laboratory chemical, not a prescribed drug for people, and USADA warns that BPC-157 is not approved for human clinical use by any global regulatory authority 1.
Why many online listings say “research use only”
“Research use only” usually means the seller is not presenting the product as a medication for a person. That label does not prove the vial is sterile, correctly dosed, clinically tested, or safe to inject.
This matters because BPC-157 is often marketed for tendon healing, ligament healing, gut support, wound healing, soft tissue healing, and recovery. Those are medical claims. For people, the evidence base has not reached the standard used for FDA-approved medications 1.
Why buying a peptide online is different from getting a prescription medication
A prescription path starts with a clinician asking what problem is being treated, what else could be causing it, and whether a medication is appropriate. An online research peptide purchase usually skips diagnosis, drug-interaction review, sterile handling review, follow-up, and side-effect monitoring.
What patients should avoid
- Do not self-inject an unlabeled or research-use peptide bought online.
- Do not rely on influencer protocols or unsupported dosing claims.
- Do not use BPC-157 to delay care for an injury, severe pain, bleeding, fever, neurologic symptoms, or ongoing gut symptoms.
- Do not assume a certificate of analysis proves a product is clinically safe or effective.
What is BPC-157?
BPC-157 stands for Body Protection Compound-157. It is commonly described as a synthetic 15-amino-acid peptide related to a protein fragment studied in gastric juice and tissue-repair models 3.
You may see BPC-157 listed as BPC-157 free base or BPC-157 acetate. There is no FDA-approved brand name for BPC-157 and no FDA-approved generic INN for BPC-157 as a human medication.
Common marketing claims
Online sellers often claim BPC-157 supports gut health, tendon healing, ligament healing, wound healing, liver protection, or exercise recovery. The safer wording is that BPC-157 has been investigated in preclinical models for gastrointestinal injury, blood-vessel signaling, fibroblast migration, collagen-related repair, and tissue injury 3.
A peptide is not automatically safe because it is made of amino acids. Insulin is a peptide hormone and can be lifesaving when prescribed correctly, but dangerous when used incorrectly. The same basic point applies here: structure alone does not prove safety, dose, quality, or benefit.
Is BPC-157 FDA-approved or legal to use as a medication?
BPC-157 is not FDA-approved as a human medication. FDA approval status is different from online availability, research interest, or advisory-committee discussion.
FDA’s Pharmacy Compounding Advisory Committee, or PCAC, reviewed BPC-157-related bulk substances during its July 23-24, 2026 meeting. The FDA docket listed BPC-157 acetate and BPC-157 free base, with ulcerative colitis among the evaluated use categories 2.
On July 23, 2026, PCAC recommended BPC-157 for inclusion on the 503A Bulks List by an 8-6-1 vote. The same meeting reviewed several other peptides; six of seven reviewed peptides were recommended, while Emideltide/DSIP was not recommended. FDA staff had proposed against all seven, and PCAC overrode that recommendation for six of them 2, 8.
What the 503A Bulks List discussion means and does not mean
A 503A Bulks List discussion is about whether a bulk drug substance may be used by certain state-licensed compounding pharmacies under federal compounding rules. It is not the same as FDA approval of a drug for safety and effectiveness 2, 5.
Compounded medications can be clinically useful when prescribed after a medical evaluation and prepared by a licensed pharmacy. But compounded drugs are not FDA-approved, and FDA does not evaluate them for safety, effectiveness, or manufacturing quality before they are dispensed 6.
Why research chemicals are not patient-ready drugs
Research chemicals are usually not dispensed with a clinician’s diagnosis, prescription, patient-specific instructions, adverse-event plan, or follow-up. FDA has warned that compounded and non-approved products can raise quality risks when they are made, sold, or used outside appropriate safeguards 6, 7.
What does the evidence actually show for BPC-157?
Most BPC-157 evidence is preclinical, meaning animal or cell research. That type of science can explain possible mechanisms, but it cannot prove that a treatment heals injuries, protects the liver, or improves gut disease in people.
Animal and cell research on wound healing and tissue repair
Peer-reviewed reviews describe BPC-157 research in wound, tendon, muscle, nerve, and soft-tissue injury models. Proposed mechanisms include effects on fibroblast migration, collagen-related repair, endothelial protection, and angiogenesis, which means new blood-vessel formation 3.
Those mechanisms are biologically interesting. They are not proof that a person with a tendon tear, ligament sprain, surgical wound, or chronic pain will improve with BPC-157.
Animal research on gastrointestinal injury and ulcerative colitis-related models
BPC-157 has also been studied in preclinical gastrointestinal injury models. The FDA PCAC meeting materials identified ulcerative colitis as a reviewed use category for BPC-157-related bulk substances, but that review does not establish BPC-157 as a proven ulcerative colitis medication 2.
Ulcerative colitis can cause bleeding, anemia, weight loss, infection risk, and cancer risk over time 9. Anyone with possible inflammatory bowel disease should be evaluated by a licensed clinician rather than relying on an online peptide.
Blood vessels, nitric oxide, VEGF, and angiogenesis
Some BPC-157 research focuses on blood-vessel biology, including nitric oxide pathways, vascular endothelial growth factor, also called VEGF, endothelial protection, and angiogenesis 3. These pathways matter in healing, but changing a pathway in a lab model is not the same as a proven clinical outcome in humans.
What is missing
What is missing is the key human evidence patients need: large, well-controlled trials that define who benefits, what dose was studied, how long treatment lasted, what side effects occurred, and what long-term risks appeared. USADA notes that because BPC-157 has not been extensively studied in humans, safe dosing and safe use for specific medical conditions are unknown 1.
Does BPC-157 protect the liver or heal injuries?
No proven human claim can be made that BPC-157 protects the liver, heals tendons, heals ligaments, or repairs injuries. The honest answer is that these ideas come mainly from preclinical research and online marketing, not established patient outcomes.
Preclinical studies discuss organ-protection and tissue-repair mechanisms, including cytoprotection, vascular effects, inflammation-related pathways, fibroblast activity, and collagen-related repair 3. But liver disease and orthopedic injuries have many causes, and treatment depends on the diagnosis.
The downside of treating “liver protection” or “injury healing” as a peptide problem is delay. A torn tendon, stress fracture, autoimmune bowel disease, hepatitis, medication-related liver injury, or infection needs the right evaluation, not a research-use vial.
What are the downsides of taking online peptides?
Online peptides can carry several risks: unknown human dose, uncertain long-term safety, incorrect strength, contamination, infection from self-injection, drug-testing consequences, and delay of evidence-based care.
- Unknown human dosing: because BPC-157 has not been well studied in humans, USADA states that no one knows whether there is a safe dose for treating specific conditions 1.
- Purity and sterility risk: a vial may not contain what the label says, may have the wrong strength, or may not be sterile enough for injection.
- Injection risk: self-injection can lead to skin injury, abscess, bloodstream infection, allergic reaction, or dosing mistakes 10.
- Athlete risk: BPC-157 is prohibited under WADA’s S0 Unapproved Substances category, and USADA warns athletes not to use it 1, 4.
- Medical-delay risk: pain, gut symptoms, and fatigue can signal conditions that need diagnosis and standard treatment.
How should patients compare online BPC-157 sellers with licensed medical care?
The key difference is oversight. A research-use peptide vendor sells a product; licensed medical care starts with a clinical question, reviews risks, and monitors the person over time.
| Question | Research-use peptide vendors | Clinician-reviewed prescription care |
|---|---|---|
| Main purpose | Usually labeled for laboratory or research use | Evaluates a person’s symptoms, goals, history, and risks |
| Medical diagnosis | Not provided | Provider reviews whether symptoms need testing, imaging, referral, or medication |
| Dosing | Often based on marketing claims or online protocols | Provider-guided when a medication is clinically appropriate |
| Quality controls | May show a certificate of analysis, but this does not prove clinical safety | Medication is dispensed by a licensed pharmacy when prescribed |
| Follow-up | Usually none | Care team can monitor side effects, contraindications, and response |
| BPC-157 status | Often sold online despite lack of FDA approval for human use | Chia does not prescribe or sell BPC-157 |
Why certificates of analysis do not prove clinical safety
A certificate of analysis may report purity or identity testing for a batch. It does not prove the product was made for human injection, that the dose is safe, that it works for an injury or gut condition, or that it is legal to use as a medication.
Questions to ask a clinician before using any peptide or compounded medication
- What diagnosis are we treating, and what else could explain my symptoms?
- Is there a standard evaluation I should complete first?
- What human evidence supports this option for my goal?
- What side effects, contraindications, and drug interactions matter for me?
- How will we monitor safety and decide whether to stop?
- Is the medication being dispensed by a licensed pharmacy?
Does Chia offer BPC-157 online?
Chia does not offer BPC-157 online, by injection, by capsule, or through a protocol. If a treatment is not listed in our current catalog, we do not state or imply that it is available through Chia.
What we do offer is clinician-reviewed access to listed treatments only. Current Chia peptide and longevity options include Sermorelin, NAD+, Glutathione, GHK-Cu Cream, and PT-141 Nasal, plus listed protocols such as Foundation Longevity.
| Chia option | Forms Chia offers | Current starting price | How it is accessed |
|---|---|---|---|
| Sermorelin | Injection, nasal spray, tablets | Injection from $179/mo; nasal spray from $179/mo | Online questionnaire, licensed-provider review, prescription only if appropriate |
| NAD+ | Injection, nasal spray | Injection from $179/mo; nasal spray from $119/mo | Online questionnaire, licensed-provider review, 503A pharmacy fulfillment when prescribed |
| Glutathione | Injection, nasal spray | Injection from $179/mo; nasal spray from $179/mo | Online questionnaire, licensed-provider review, home delivery when prescribed |
| GHK-Cu Cream | Cream | From $159/mo | Online questionnaire, licensed-provider review, 503A pharmacy fulfillment when prescribed |
| Foundation Longevity | Sermorelin Injection + NAD+ Injection + Glutathione Injection | From $399/mo | Protocol review by a licensed provider; prescription not guaranteed |
Chia’s process is 100% online: you complete a short health questionnaire, a licensed US provider reviews it, and a prescription is written only where clinically appropriate. Medications Chia offers are compounded in the US by state-licensed 503A pharmacies and shipped to the patient’s door.
If your real question is “What should I do about pain, injury recovery, gut symptoms, energy, or longevity goals?” the safer next step is a clinical review rather than buying a research peptide. You can start with Chia’s eligibility quiz, knowing that BPC-157 itself is not offered and a prescription is never guaranteed.
What are alternatives to BPC-157?
There is no direct substitute for BPC-157 because BPC-157 is not an established human treatment. The better approach is condition-first care: define the problem, then choose evidence-based evaluation and treatment.
- Pain or injury: consider a medical exam, physical therapy, imaging when needed, and a plan for return to activity.
- Gut symptoms: persistent diarrhea, bleeding, weight loss, fever, or severe pain should be evaluated promptly.
- Fatigue or recovery goals: sleep, nutrition, training load, thyroid disease, anemia, medication effects, and mental health can all matter.
- Longevity goals: a clinician can help separate measurable health risks from unproven claims.
Some Chia treatments may be discussed if they match a patient’s goals and medical history, such as NAD+, Glutathione, Sermorelin, or GHK-Cu Cream. These are not direct replacements for BPC-157 and should not be used to self-treat an injury, ulcerative colitis, liver disease, or any undiagnosed symptom.
FAQ
Human safety is not established. BPC-157 has not been extensively studied in people, so safe dosing, long-term risks, and benefits for specific conditions remain uncertain.
FDA’s PCAC recommended BPC-157 for possible inclusion on the 503A Bulks List in July 2026, but that vote is advisory. FDA’s final determination is pending, so patients should check FDA.gov for the current status.
No. BPC-157 and TB-500 are different peptides. They are often marketed in similar recovery or tissue-repair categories, but they have different structures and evidence bases.
Competitive athletes should not use BPC-157 unless their sport’s anti-doping authorities clearly allow it. BPC-157 is prohibited under WADA’s S0 Unapproved Substances category.
It is not proven to heal tendons or ligaments in humans. Most claims come from animal or cell research, not large controlled human trials.
BPC-157 has been discussed in relation to ulcerative colitis models and FDA compounding review, but it is not an FDA-approved ulcerative colitis medication. People with symptoms should seek medical care.
Do not use this article as injection guidance. Self-injecting a research-use peptide can carry infection, dosing, sterility, and safety risks. Talk with a licensed clinician.
If you have side effects, injection-site redness, fever, swelling, worsening pain, allergic symptoms, or new health concerns, contact a clinician promptly. Bring the product label or vial information if you have it.
References
- 1.U.S. Anti-Doping Agency. BPC-157: Experimental Peptide Creates Risk for Athletes. USADA, 2024.
- 2.U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA, 2026.
- 3.Sikiric P, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide. International Journal of Molecular Sciences, 2025.
- 4.World Anti-Doping Agency. The 2026 Prohibited List: International Standard. WADA, 2026.
- 5.U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA, 2026.
- 6.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA, 2024.
- 7.U.S. Food and Drug Administration. The Special Risks of Pharmacy Compounding. FDA, 2023.
- 8.Drug Topics. FDA Pharmacy Compounding Advisory Committee Recommends Several Peptides for 503A Bulks List Consideration. Drug Topics, 2026.
- 9.National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms & Causes of Ulcerative Colitis. NIDDK, 2024.
- 10.Centers for Disease Control and Prevention. Injection Safety. CDC, 2024.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if NAD+ is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
